EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Study
EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Feasibility and Long Term Outcome
Sponsor: Asan Medical Center
A NA clinical study on Efficacy and Feasibility, this trial is ongoing. The trial is conducted by Asan Medical Center and has accumulated 7 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown NA
-
Sep 2024 — Sep 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status NA
-
Dec 2018 — Jan 2021 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Dec 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Asan Medical Center
- Dankook University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Seoul, South Korea